Abaloparatide is a selective activator of the parathyroid hormone type 1 (PTH1) receptor and is used for the treatment of osteoporosis in postmenopausal women at high risk of fracture or who are unresponsive to other therapies. Administered via subcutaneous injection, it effectively reduces the incidence of new vertebral and non-vertebral fractures. Compared to teriparatide, abaloparatide demonstrates superior efficacy in reducing fracture rates and the incidence of hypercalcemia. Due to its potent anabolic activity on bone, abaloparatide has been developed clinically for the treatment of osteoporosis in postmenopausal women with a high risk of fracture.